{"id":519843,"date":"2021-07-29T08:04:30","date_gmt":"2021-07-29T12:04:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-senior-leadership-additions\/"},"modified":"2021-07-29T08:04:30","modified_gmt":"2021-07-29T12:04:30","slug":"rhythm-pharmaceuticals-announces-senior-leadership-additions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-senior-leadership-additions\/","title":{"rendered":"Rhythm Pharmaceuticals Announces Senior Leadership Additions"},"content":{"rendered":"
\n

\n — Pamela Cramer appointed Chief Human Resources Officer —<\/em>
\n \n <\/p>\n

\n — Linda Shapiro Manning, M.D., Ph.D., appointed Senior Vice President, Clinical —<\/em>\n <\/p>\n

BOSTON, July 29, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the appointments of Pamela Cramer as Chief Human Resources Officer and Linda Shapiro Manning, M.D., Ph.D., as Senior Vice President, Clinical.<\/p>\n

\u201cWe are excited to welcome Pam and Linda to the Rhythm team at a transformational time for the company, as we work to deliver IMCIVREE\u2122 (setmelanotide) to patients with certain rare genetic diseases of obesity in the United States and Europe and expand our reach with a multi-faceted, global clinical development strategy,\u201d said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. \u201cPam brings deep talent management and organizational development experience and a strong track record as an effective business partner, and Linda comes with significant clinical experience in obesity, both as a practicing physician and clinical development leader in industry. We are thrilled both senior leaders chose to join us and look forward to their contributions as we execute on our mission.\u201d<\/p>\n

Ms. Cramer joined Rhythm as Chief Human Resources Officer, effective July 26. She brings 20 years of leadership experience in organizational effectiveness, talent development and human resources (HR) transformation with globally diverse life sciences and financial services companies. She joins Rhythm from Foundation Medicine, where she most recently served as Head of People Solutions and was responsible for leading HR delivery for its more than 1700 employees. Prior to that, Ms. Cramer held senior HR positions at Cambridge Associates, PAREXEL International and Epsilon Data Management. Earlier in her career, Ms. Cramer served in a wide range of positions at Bank of America Merrill Lynch and General Electric, where she began her career as a graduate of the Human Resources Leadership Program. She holds an M.B.A. from Georgetown University.<\/p>\n

Dr. Shapiro joined Rhythm earlier in July, bringing more than 20 years of experience in obesity medicine. For the past ten years, she has worked in the biopharmaceutical industry, with clinical development and medical affairs roles at Applied Therapeutics, Boehringer Ingelheim, Merck and Novo Nordisk. In these roles, she led clinical development for assets in type 2 diabetes and cardiometabolic conditions and, at Novo Nordisk, she served as head of medical science and international medical director for the company\u2019s GLP-1 and obesity global development programs. Prior to joining industry, Dr. Shapiro practiced medicine in Colorado, obtaining certification and specializing in obesity medicine. She holds a Ph.D. and completed a post-doctoral research fellowship in kinesiology and applied physiology from the University of Colorado, an M.D. from Tulane University School of Medicine, and a bachelor\u2019s degree in exercise science from the University of Southern California.<\/p>\n

\n About\u00a0Rhythm Pharmaceuticals<\/strong>
\n
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. The Company\u2019s precision medicine, IMCIVREE (setmelanotide), was approved in November 2020 by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing and by the European Commission (EC) in July 2021 for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE is the first-ever FDA-approved and EC-authorized therapy for these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity. The Company is leveraging the Rhythm Engine and the largest known obesity DNA database\u00a0\u2013 now with approximately 37,500 sequencing samples\u00a0\u2013 to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. The company is based in Boston, MA.<\/p>\n

\n IMCIVREE<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (setmelanotide) Indication<\/strong>
\n
In the United States, IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin\/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The condition must be confirmed by genetic testing demonstrating variants in\u00a0POMC<\/em>,\u00a0PCSK1<\/em>, or\u00a0LEPR<\/em>\u00a0genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VOUS).<\/p>\n

In the EU, IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.<\/p>\n

\n Limitations of Use<\/strong>
\n
IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:<\/p>\n